GVK Bio is now known as Aragen. How is the name change going to have an impact on the brand?
The re-branding exercise has given us an opportunity to re-discover ourselves as an organisation and build upon it. The company has grown from strength to strength over the last 20 years. While our values remain the same, it is now aligned to the new brand promise and purpose, something that is imbibed by each and every employee of the organisation. This rebranding initiative enabled us to streamline and bring in a clear focus to our vision for success. Aragen is a name known for its scientific expertise and customer-centric culture in the West. We are now investing in branding around the name – our initial feedback from both current and prospective customers has been very positive. They love our new identity and our renewed purpose and promise. The number of positive responses in the social media from all our internal and external stakeholders is a testimony to the liking of our new identity. This new brand identity is well poised to launch Aragen into this exciting future.
What are the plans in store following the recent investment by Goldman Sachs?
Continue reading your story on the app
Continue reading your story in the magazine
How Tech Innovations Impact Cardiac Care
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
Mynvax Offers ‘Warm Vaccine' For COVID-19
Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.
“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”
Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.
SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future
The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!
Merck launches Pergoveris Pen for fertility treatment in India
Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation
CEPI prioritises Rift Valley fever vax
Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.
3D printing moulds healthcare innovations
Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.
The Healthy Habit of Sauca
How cultivating cleanliness inside and out-can bring you peace of mind.
BELLANDUR LAKE FROTH - Debasish Ghosh
Bangalore, India, was once known for its interconnected lake systems, which provided a reliable water source. As the city grew, these lakes have encroached, and the water became polluted day by day. The largest, Bellandur Lake, now carry huge volumes of snowy froth, which block the adjacent canals.
K'taka revenue intelligence sleuths smash wildlife smuggling racket
THE Directorate of Revenue Intelligence (DRI), Bengaluru, has busted an international wildlife syndicate which trafficked endangered wildlife species though mobile apps, in a massive operation codenamed 'Kalki'.
No new variants found in genomic testing
THE third genomic testing report released this week has shown no new variants of Covid-19 in the positive samples that were collected from across the city and the airport.
Are millets really the only grains you need?
While millets are great for you, blindly replacing the rice and wheat in your pantry with vast quantities of millets is inadvisable
'Leasing of retail space up 21% in 2022 across 8 cities'
Leasing of retail real estate space during last year rose 21 percent to 4.7 million square feet across eight major cities mainly on rising demand from Food and Beverage (F&B), fashion and apparel retailers, according to CBRE India.
DEVELOPMENT AND THE PRICE THAT COMES WITH IT
Big cities like Bengaluru are losing their soul. The priorities we chase are about brick, mortar, money, growth and what falls under the crass umbrella of the \"development\" word
rhythms of bengaluru
The Garden City has a charm like no other; you can go park hopping or pub hopping depending on what time of the day it is, or what the mood is. Soak in Bengaluru's easy charm with Jayshree Poddar, Deena Rodrigues, Nain Beliappa, Radheesh Shetty, Uma Rao, Kavya Seth and Shruti Jaipuria
'B'luru-Chennai expressway to be ready by March'24'
New greenfield project being implemented at a cost of ₹17,000 crore, says Nitin Gadkari
Zip from B'luru to Chennai in 2.15 hrs by 2024: Gadkari
FROM March 2024, people can zip from Bengaluru to Chennai in 2 hours 15 minutes at a speed of 120km/hour, Union Transport Minister Nitin Gadkari said on Thursday, after inspecting the progress of the new 8-lane, 262-km Bengaluru-Chennai Expressway at Vadaganahalli, on the outskirts of Bengaluru.